NASDAQ:LIPO Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis $0.63 -0.09 (-12.92%) As of 07/25/2025 01:06 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lipella Pharmaceuticals Stock (NASDAQ:LIPO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LIPO alerts:Sign Up Key Stats Today's Range$0.63▼$0.8050-Day Range$0.63▼$3.0952-Week Range$0.62▼$12.00Volume5,193 shsAverage Volume1.00 million shsMarket Capitalization$2.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. Read More Lipella Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreLIPO MarketRank™: Lipella Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lipella Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipella Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipella Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipella Pharmaceuticals has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lipella Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.27% of the float of Lipella Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLipella Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipella Pharmaceuticals has recently decreased by 87.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLipella Pharmaceuticals does not currently pay a dividend.Dividend GrowthLipella Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.27% of the float of Lipella Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLipella Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipella Pharmaceuticals has recently decreased by 87.59%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for LIPO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lipella Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders32.11% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lipella Pharmaceuticals' insider trading history. Receive LIPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LIPO Stock News HeadlinesLIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | MorningstarJuly 18, 2025 | morningstar.comMLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - MorningstarJune 27, 2025 | morningstar.comMBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. July 26 at 2:00 AM | Crypto 101 Media (Ad)Lipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operationsJune 27, 2025 | bizjournals.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 26, 2025 | finanznachrichten.deLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 25, 2025 | globenewswire.comNasdaq delists Lipella Pharmaceuticals over rule violationsJune 22, 2025 | investing.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 21, 2025 | finanznachrichten.deSee More Headlines LIPO Stock Analysis - Frequently Asked Questions How have LIPO shares performed this year? Lipella Pharmaceuticals' stock was trading at $3.05 at the beginning of 2025. Since then, LIPO shares have decreased by 79.4% and is now trading at $0.6270. How were Lipella Pharmaceuticals' earnings last quarter? Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.64) earnings per share for the quarter. The firm had revenue of $0.13 million for the quarter. Lipella Pharmaceuticals had a negative trailing twelve-month return on equity of 224.08% and a negative net margin of 988.83%. When did Lipella Pharmaceuticals' stock split? Lipella Pharmaceuticals shares reverse split on Friday, November 8th 2024.A 1-8 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Lipella Pharmaceuticals IPO? Lipella Pharmaceuticals (LIPO) raised $7 million in an IPO on Tuesday, December 20th 2022. The company issued 1,217,391 shares at $5.75 per share. How do I buy shares of Lipella Pharmaceuticals? Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lipella Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), NVIDIA (NVDA), Heatwurx (PCSA), Energy Transfer (ET), Labor Smart (LTNC) and NIO (NIO). Company Calendar Last Earnings5/14/2025Today7/26/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIPO CIK1347242 Weblipella.com Phone412-901-0315FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.02 million Net Margins-988.83% Pretax Margin-988.63% Return on Equity-224.08% Return on Assets-172.88% Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio6.21 Sales & Book Value Annual Sales$536.36 thousand Price / Sales5.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book0.39Miscellaneous Outstanding Shares4,467,000Free Float3,033,000Market Cap$2.80 million OptionableNot Optionable Beta-0.08 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:LIPO) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.